Relationship of neurotransmitters to the symptoms of major depressive disorder.
about
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathwayA phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorderMilnacipran: a unique antidepressant?Oxidative Stress Implications in the Affective Disorders: Main Biomarkers, Animal Models Relevance, Genetic Perspectives, and Antioxidant ApproachesPathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic ReviewRole of Sirtuins in Linking Metabolic Syndrome with DepressionCircadian Rhythms and Mood Disorders: Are the Phenomena and Mechanisms Causally Related?5-HTTLPR, HTR1A, and HTR2A cumulative genetic score interacts with mood reactivity to predict mood-congruent gaze bias.Levomilnacipran for the treatment of major depressive disorder: a reviewOn the Complexity of Brain Disorders: A Symptom-Based Approach.Loss of NMDA receptors in dopamine neurons leads to the development of affective disorder-like symptoms in mice.Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats.Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trialsPrenatal alcohol exposure: fetal programming and later life vulnerability to stress, depression and anxiety disordersImprovement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors.Estrogens of multiple classes and their role in mental health disease mechanisms.The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled studyAntidepressant-like effects of the hydroalcoholic extracts of Hemerocallis citrina and its potential active components.The importance of norepinephrine in depression.Improvement of the noradrenergic symptom cluster following treatment with milnacipran.Essential amino acids in the gluten-free diet and serum in relation to depression in patients with celiac disease.Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.Low-Level Laser Irradiation Improves Depression-Like Behaviors in Mice.Levomilnacipran Extended-Release Treatment in Patients With Major Depressive Disorder: Improvements in Functional Impairment Categories.Involvement of the cerebral monoamine neurotransmitters system in antidepressant-like effects of a chinese herbal decoction, baihe dihuang tang, in mice model.Reaching out to people struggling with their lives: a discourse analysis of answers from Internet-based services in Norway and Sweden.Valerenic Acid Protects Against Physical and Psychological Stress by Reducing the Turnover of Serotonin and Norepinephrine in Mouse Hippocampus-Amygdala RegionEffects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.Depressive Symptoms and Risk of Postoperative Delirium.The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.PNI Biomarkers and Health Outcomes in College WomenMicroRNA as therapeutic targets for treatment of depression.Alterations in circadian entrainment precede the onset of depression-like behavior that does not respond to fluoxetine.The dynamic effects of nicotine on the developing brain.Disruption of circadian rhythms: a crucial factor in the etiology of depression.Mitochondrial Dysfunction in Depression.Antidepressant-like behavioral, anatomical, and biochemical effects of petroleum ether extract from maca (Lepidium meyenii) in mice exposed to chronic unpredictable mild stress.P300 latency as an indicator of severity in major depressive disorderDevelopment and evaluation of Desvenlafaxine loaded PLGA-chitosan nanoparticles for brain deliveryEffects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.
P2860
Q21559605-56059594-0D3D-40C9-97E7-04783AE7E2B2Q24564427-3A20A522-5A50-4A67-8D81-21DF230BD066Q24610271-C679902B-9226-4CE0-8D3E-F8F99C86C517Q26738789-A8582E68-E6CC-4E13-A6FD-06D94529057BQ26749017-D4AEFDA7-DD68-42AD-B6A8-1B0F8E0D4E81Q26749937-5133CE5E-7675-4D8E-8110-5B2AF496592FQ26784870-7F5B9471-5B29-4EEF-9C40-83C5B20A57D6Q27303044-EC488448-8014-4A19-BEC9-C25FE5C6FC30Q28083216-BE667C1C-87C5-416B-BAE6-6D625E9BE230Q30389213-A79B3243-C6A0-4B01-A1ED-61FE3E158BF7Q30828943-FE1B76CA-6F24-4AB5-BA5F-6E20138DDD1FQ33624583-32DBB921-AF7C-4F54-BE13-2BEDF03EA03DQ33718213-03838322-2679-4252-B676-4473609688C7Q33919857-CD84134C-3662-4637-88C6-4F69A4328CD0Q34184179-CC60B673-FBD4-4C50-83E2-0C6E3FF131D9Q34272184-3070DB39-4F6C-423D-8DA7-4AEE4D10F40CQ34531579-0AEA8F51-BBDD-433F-835B-697064A6C639Q34897016-E1003980-B36C-4BE1-AC18-ACE90F1CE3B7Q35090223-3A66BBA3-1B4F-4F5D-A850-F0C60BC75139Q35090230-416DF1EA-E8C2-4334-9BE7-C19A44DAA856Q35464761-D1359DD7-98F9-4317-A470-C82503C34432Q35596249-5CDA3603-DC38-4078-9A2D-ECCC35F426C1Q36068192-1B48D16C-0A05-4758-8EE2-29B0CD7D2D68Q36083249-D44AB00A-7CBE-4F30-A885-7D3224467DA8Q36205870-7347D6F1-FA6D-430B-89BF-88735A391CA4Q36284038-54660690-5D14-4A3C-958F-96A499EB159CQ36388476-E46BD902-3BB1-44AA-A5F8-CAE0291B96D8Q36530043-27FB3649-7C86-4DFF-8D9C-CE349DF70F50Q36712064-EF140517-BFD7-40E8-B5CF-B8B26902A2E5Q36781720-F9F3205E-E234-43EB-8F6D-E756104BBFC1Q37069138-E7AB8CFB-BF30-4C7A-940F-D30544D4D5ABQ37075039-2A0D9139-16D2-4CB3-9067-704A4F97615BQ37347588-1741226A-B906-4410-ABAF-370BE834A1D6Q37352445-6D3768B6-A328-41E3-AA9B-9E1024BB15A1Q37918401-453784F2-360C-4909-A307-1989D866152AQ38753778-627C831C-F70F-4D5E-9BCF-7DFAF769CEDFQ39729826-BA9C4BD6-FDEB-4997-A58C-0FBC364A3F92Q39744822-9546C8A0-F76A-4A3B-9F28-FE2CF174231EQ41690505-8EC57F4D-F3CB-4969-8485-89077F6CFB63Q42176639-65841BAC-2295-4B34-B79C-D9E683F792D7
P2860
Relationship of neurotransmitters to the symptoms of major depressive disorder.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@ast
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@en
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@nl
type
label
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@ast
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@en
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@nl
prefLabel
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@ast
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@en
Relationship of neurotransmitters to the symptoms of major depressive disorder.
@nl
P1476
Relationship of neurotransmitters to the symptoms of major depressive disorder
@en
P478
69 Suppl E1
P50
P577
2008-01-01T00:00:00Z